301 related articles for article (PubMed ID: 37473778)
21. Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.
Goyal A; Romero-Severson EO
PLoS One; 2018; 13(9):e0203831. PubMed ID: 30192887
[TBL] [Abstract][Full Text] [Related]
22. [Delta hepatitis in Africa: epidemiological and clinical particularities].
Lunel Fabiani F; El Bara A; Hamed CT; LE Guillou Guillemette H
Med Trop Sante Int; 2023 Dec; 3(4):. PubMed ID: 38390020
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis delta virus: From infection to new therapeutic strategies.
Niro GA; Ferro A; Cicerchia F; Brascugli I; Durazzo M
World J Gastroenterol; 2021 Jun; 27(24):3530-3542. PubMed ID: 34239267
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis delta infection among persons living with HIV in Europe.
Béguelin C; Atkinson A; Boyd A; Falconer K; Kirkby N; Suter-Riniker F; Günthard HF; Rockstroh JK; Mocroft A; Rauch A; Peters L; Wandeler G;
Liver Int; 2023 Apr; 43(4):819-828. PubMed ID: 36625770
[TBL] [Abstract][Full Text] [Related]
25. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies.
Kamal H; Fornes R; Simin J; Stål P; Duberg AS; Brusselaers N; Aleman S
J Viral Hepat; 2021 Oct; 28(10):1431-1442. PubMed ID: 34291520
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis D virus: Improving virological knowledge to develop new treatments.
Khalfi P; Kennedy PT; Majzoub K; Asselah T
Antiviral Res; 2023 Jan; 209():105461. PubMed ID: 36396025
[TBL] [Abstract][Full Text] [Related]
27. Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus.
Asselah T
J Viral Hepat; 2023 Apr; 30 Suppl 1():33-38. PubMed ID: 36529713
[TBL] [Abstract][Full Text] [Related]
28. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians.
Chen X; Oidovsambuu O; Liu P; Grosely R; Elazar M; Winn VD; Fram B; Boa Z; Dai H; Dashtseren B; Yagaanbuyant D; Genden Z; Dashdorj N; Bungert A; Dashdorj N; Glenn JS
Hepatology; 2017 Dec; 66(6):1739-1749. PubMed ID: 27880976
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.
Ferrante ND; Lo Re V
Curr HIV/AIDS Rep; 2020 Aug; 17(4):405-414. PubMed ID: 32607773
[TBL] [Abstract][Full Text] [Related]
30. Hepatitis D virus coinfection and superinfection.
Negro F
Cold Spring Harb Perspect Med; 2014 Nov; 4(11):a021550. PubMed ID: 25368018
[TBL] [Abstract][Full Text] [Related]
31. A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction.
Suárez-Amarán L; Usai C; Di Scala M; Godoy C; Ni Y; Hommel M; Palomo L; Segura V; Olagüe C; Vales A; Ruiz-Ripa A; Buti M; Salido E; Prieto J; Urban S; Rodríguez-Frias F; Aldabe R; González-Aseguinolaza G
J Hepatol; 2017 Oct; 67(4):669-679. PubMed ID: 28527664
[TBL] [Abstract][Full Text] [Related]
32. Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: a cross sectional study.
Lunel-Fabiani F; Mansour W; Amar AO; Aye M; Le Gal F; Malick FZ; Baïdy L; Brichler S; Veillon P; Ducancelle A; Gordien E; Rosenheim M
J Infect; 2013 Nov; 67(5):448-57. PubMed ID: 23796871
[TBL] [Abstract][Full Text] [Related]
33. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories.
Polaris Observatory Collaborators
J Hepatol; 2024 Feb; 80(2):232-242. PubMed ID: 38030035
[TBL] [Abstract][Full Text] [Related]
34. New epidemiology of hepatitis delta.
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2020 Feb; 40 Suppl 1():48-53. PubMed ID: 32077599
[TBL] [Abstract][Full Text] [Related]
35. Seroprevalence and epidemiological characteristics of HDV infection among HBV patients in the Nile Delta, Egypt.
Elzefzafy W; Soliman R; Saleh L; Mahmoud S; Makhlouf NA; Shiha G; Zaky S
J Viral Hepat; 2022 Jan; 29(1):87-90. PubMed ID: 34582608
[TBL] [Abstract][Full Text] [Related]
36. Dynamics of in vivo hepatitis D virus infection.
Goyal A; Murray JM
J Theor Biol; 2016 Jun; 398():9-19. PubMed ID: 27012516
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis delta: virological and clinical aspects.
Botelho-Souza LF; Vasconcelos MPA; Dos Santos AO; Salcedo JMV; Vieira DS
Virol J; 2017 Sep; 14(1):177. PubMed ID: 28903779
[TBL] [Abstract][Full Text] [Related]
38. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia.
Tsatsralt-Od B; Takahashi M; Nishizawa T; Endo K; Inoue J; Okamoto H
J Med Virol; 2005 Dec; 77(4):491-9. PubMed ID: 16254981
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis D Virus and Hepatocellular Carcinoma.
Farci P; Niro GA; Zamboni F; Diaz G
Viruses; 2021 May; 13(5):. PubMed ID: 34064419
[TBL] [Abstract][Full Text] [Related]
40. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference.
Jardi R; Rodriguez F; Buti M; Costa X; Cotrina M; Galimany R; Esteban R; Guardia J
Hepatology; 2001 Aug; 34(2):404-10. PubMed ID: 11481626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
